UNC PrEP Study: DISCOVER
A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection.
Study Name |
Gilead “DISCOVER Study” |
Full title |
A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection. |
Purpose |
To assess the effectiveness of F/TAF (Descovy) at preventing HIV infection.
|
Study Duration |
2-4 years |
Study Design |
Step one:
Step two:
|
|
Screen, Entry, Week 4, Week 12 and then visits take place every 12 weeks (wk. 24, wk. 36, etc.).
|
Side effects |
|
Major inclusion criteria |
|
Major exclusion criteria |
History of osteoporosis/bone fragility, use of defibrillator or pacemaker, HIV positive, co-enrollment in study for HIV prevention agents, liver or kidney abnormalities
|
Payment |
$50/visit |
Location |
Chapel Hill, Raleigh (Blue Ridge & Wake), and Durham (Blue City Business Center) |
Primary investigator |
David Wohl, MD Contact Information: 1-877-643-9040 |